MedElevator Войти в исследования
← Поиск публикаций

DOI 10.11406/rinketsu.57.2481

Медицинская библиотека · [Rinsho ketsueki] The Japanese journal of clinical hematology · 2016

[Retrospective analysis of clinical outcomes of the patients with chronic myeloid leukemia who stopped administration of tyrosine kinase inhibitors: a single institution experience].

Senoo Yasushi, Yoshioka Kosuke, Kaito Satoshi, Kurosawa Shuhei, Harada Kaito, Yamamoto Keita, Hino Yutaro, Sakaguchi Masahiro, Ikegawa Shuntaro, Watanabe Daisuke, Watakabe Kyoko, Hagino Takeshi, Igarashi Aiko, Najima Yuho, Doki Noriko, Kobayashi Takeshi, Kakihana Kazuhiko, Sakamaki Hisashi, Ohashi Kazuteru

СтатьяПеревод пока не подготовлен

Аннотация

We describe herein the clinical outcomes of 16 patients with chronic myeloid leukemia in the chronic phase who stopped the administration of tyrosine kinase inhibitors (TKI) after maintaining undetectable levels of major BCR-ABL1, based on real-time quantitative polymerase chain reaction, for prolonged periods (undetectable MR for a median of 2,100 days (822-4,068). The reasons for discontinuing TKI were enrollments in a clinical trial testing discontinuation of these agents (n=9), adverse effects (n=2) or financial problems (n=5). After TKI discontinuation, patients were followed for a median of 551 days (154-2,446). A total of 8 patients (50%) experienced molecular relapse after a median of 119 days (28-171). Among them, 6 patients who lost major molecular response (MMR) were treated with imatinib (n=2) or dasatinib (n=4), while 2 patients who lost undetectable MR after discontinuing TKI (1 each had taken bostinib and imatinib) but maintained MMR were carefully monitored without re-administration of TKI. Of 6 patients who re-started TKI, 4 (67%) achieved undetectable MR but the other 2 achieved only MMR. The results of this small, retrospective study may support the current understanding of treatment discontinuation, possibly leading to a sustained deep molecular response in some patients.

Для цитирования: Senoo Yasushi, Yoshioka Kosuke, Kaito Satoshi, Kurosawa Shuhei, Harada Kaito, Yamamoto Keita, Hino Yutaro, Sakaguchi Masahiro, Ikegawa Shuntaro, Watanabe Daisuke, Watakabe Kyoko, Hagino Takeshi, Igarashi Aiko, Najima Yuho, Doki Noriko, Kobayashi Takeshi, Kakihana Kazuhiko, Sakamaki Hisashi, Ohashi Kazuteru. [Retrospective analysis of clinical outcomes of the patients with chronic myeloid leukemia who stopped administration of tyrosine kinase inhibitors: a single institution experience].. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2016. DOI: 10.11406/rinketsu.57.2481.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.